Roche to Acquire PathAI for Up to $1.05 Billion to Advance AI-Powered Digital Pathology

May 07, 2026 16:13 CST Updated 16:13

PathAI

Artificial Intelligence Medical Diagnosis Technology Developer

May 7,LuoShiAnnounced the acquisition of U.S.-basedAI CompanyPathAIThe latter is a company focused on digital pathology and AI technology for the pathology laboratory and biopharmaceutical industries.

This acquisition further deepens the partnership between Roche and PathAI, which was initially established in 2021 and expanded into the field of AI-assisted diagnostic algorithm development in 2024. Prior to the expected transaction completion in the second half of this year, the acquired entity will continue to operate as part of the diagnostics division.

According to the terms of the agreement,Roche will make a one-time payment of $750 million for the acquisition and an additional payment of up to $300 million in milestone payments.

This acquisition strengthens Roche's position in the field of digital pathology, driving the industry's transition from manual operations to fully automated AI processes. By generating high-resolution digital images of tissue sections, digital pathology enables pathologists to streamline diagnoses using AI tools, helping patients receive test results more quickly.

PathAI's AISight IMS Software Seamlessly Integrates Advanced Analytical Tools with Workflow Functions through Its Efficient and Intuitive User Interface, Perfectly Meeting the Needs of Digital Pathology Laboratories. In Response to the Rapidly Growing Pathology Market, Roche Plans to Expand This Solution Globally.

Roche Diagnostics CEO Matt Sause stated, "Digital pathology has the potential to enhance the precision diagnosis of cancer, enabling doctors to offer more personalized treatment options." "Bringing PathAI into Roche Diagnostics will allow us to combine their top-tier digital pathology tools with a leading oncology diagnostics platform, providing doctors with deeper insights and potentially better treatment outcomes for patients worldwide."

PathAI CEO and co-founder Andy Beck added, "Partnering with Roche marks a new era for PathAI, enabling us to fulfill our mission of improving patient outcomes through AI-driven pathology at an unprecedented scale and speed. Roche's global infrastructure and expertise will bring our digital diagnostic technologies to patients worldwide."

End

Statement:The articles published by this official account (including original and reprinted articles) are intended to convey more information, with sources and authors clearly indicated. Feel free to share in your friend circle or large groups.Reproduction in whole or in part in any form without the permission of the media or institution is prohibited.。Reprint/Business/ContributionPlease contact

Business Cooperation

Call for Papers

Click to learn more

Previous Review

Latest! Top 30 Global Pharmaceutical Giants by Market Value

Top 10 Global Obesity Drug Enterprises in 2026 Revealed

A Comprehensive Guide to Antibodies: Structure, Classification, and ADCC/ADCP/CDC Mechanisms